English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

The incidence of renal‐related adverse events ( AEs ) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active‐ and placebo‐controlled trials ( N  = 5598) and in a 104‐week study vs glimepiride ( N  = 1450) was low and similar in canagliflozin and non‐canagliflozin groups. In the study vs glimepiride, canagliflozin was associated with an initial acute decrease in estimated glomerular filtration rate ( eGFR ) that attenuated over time, while  eGFR  declined progressively over 104 weeks with glimepiride. The incidence of renal‐related  AEs  with canagliflozin was generally stable over time, while the incidence with glimepiride increased over 104 weeks. In the present analysis, based on postmarketing reports from the  US F ood and  D rug  A dministration  A dverse  E vent  R eporting  S ystem, a potential signal was identified for acute kidney injury with all approved sodium glucose co‐transporter 2 ( SGLT2 ) inhibitors (ie, canagliflozin, dapagliflozin and empagliflozin). The early onset of acute kidney injury events with  SGLT2  inhibitors in postmarketing reports probably reflects the acute changes in  eGFR  attibutable to the known renal haemodynamic effects of  SGLT2  inhibition.

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus